A phase I trial of IMA970A plus Montanide in combination with Durvalumab (anti-PD-L1) in patients with very early, early and intermediate stage of hepatocellular carcinoma after any standard treatments.

2024-518298-33-00 Protocol HepaVac-201 Human pharmacology (Phase I) - Other Ongoing, recruitment ended

Start 21 Nov 2022 · Status Ongoing, recruitment ended · 1 EU/EEA countries · 1 sites · Protocol HepaVac-201

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruitment ended
Participants planned 10
Countries 1
Sites 1

Hepatocellular carcinoma

Key facts

Sponsor
IRCCS Istituto Nazionale Tumori Fondazione Pascale
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
21 Nov 2022 → ongoing
Decision date (initial)
2024-11-11
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2024-518298-33-00
EudraCT number
2021-002910-15
ClinicalTrials.gov
NCT06218511

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Hepatocellular carcinoma

VersionLevelCodeTermSystem organ class
20.0 LLT 10077746 Hepatocellular carcinoma stage I 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

IRCCS Istituto Nazionale Tumori Fondazione Pascale

Sponsor organisation
IRCCS Istituto Nazionale Tumori Fondazione Pascale
Address
Via Mariano Semmola 52
City
Naples
Postcode
80131
Country
Italy

Scientific contact point

Organisation
IRCCS Istituto Nazionale Tumori Fondazione Pascale
Contact name
Luigi Buonaguro

Public contact point

Organisation
IRCCS Istituto Nazionale Tumori Fondazione Pascale
Contact name
Luigi Buonaguro

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Italy Ongoing, recruitment ended 10 1
Rest of world 0

Investigational sites

Italy

1 site · Ongoing, recruitment ended
IRCCS Istituto Nazionale Tumori Fondazione Pascale
Oncologia Medica Melanoma Immunoterapia Oncologica e Terapie Innovative, Via Mariano Semmola 142, 80131, Naples

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Italy 2022-11-21 2022-11-21 2025-08-27

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-10-21 Italy Acceptable
2024-11-06
2024-11-11
2 NON SUBSTANTIAL MODIFICATION NSM-1 2025-04-08 Italy Acceptable
2024-11-06
2025-04-08